Rogier J Nell1, Nino V Menger1, Mieke Versluis1, Gregorius P M Luyten1, Robert M Verdijk2,3, Michele C Madigan4,5, Martine J Jager1, Pieter A van der Velden6. 1. Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands. 2. Department of Pathology, Leiden University Medical Center, Leiden, the Netherlands. 3. Department of Pathology, Erasmus MC University Medical Center, Rotterdam, the Netherlands. 4. Save Sight Institute and Department of Ophthalmology, University of Sydney, Sydney, Australia. 5. School of Optometry and Vision Science, University of New South Wales, Sydney, Australia. 6. Department of Ophthalmology, Leiden University Medical Center, Leiden, the Netherlands. P.A.van_der_Velden@lumc.nl.
Abstract
BACKGROUND: Activating Gαq signalling mutations are considered an early event in the development of uveal melanoma. Whereas most tumours harbour a mutation in GNAQ or GNA11, CYSLTR2 (encoding G-protein coupled receptor CysLT2R) forms a rare alternative. The role of wild-type CysLT2R in uveal melanoma remains unknown. METHODS: We performed a digital PCR-based molecular analysis of benign choroidal nevi and primary uveal melanomas. Publicly available bulk and single cell sequencing data were mined to further study mutant and wild-type CYSLTR2 in primary and metastatic uveal melanoma. RESULTS: 1/16 nevi and 2/120 melanomas carried the CYSLTR2 mutation. The mutation was found in a subpopulation of the nevus, while being clonal in both melanomas. In the melanomas, secondary, subclonal CYSLTR2 alterations shifted the allelic balance towards the mutant. The resulting genetic heterogeneity was confirmed in distinct areas of both tumours. At the RNA level, further silencing of wild-type and preferential expression of mutant CYSLTR2 was identified, which was also observed in two CYSLTR2 mutant primary melanomas and one metastatic lesion from other cohorts. In CYSLTR2 wild-type melanomas, high expression of CYSLTR2 correlated to tumour inflammation, but expression originated from melanoma cells specifically. CONCLUSIONS: Our findings suggest that CYSLTR2 is involved in both early and late development of uveal melanoma. Whereas the CYSLTR2 p.L129Q mutation is likely to be the initiating oncogenic event, various mechanisms further increase the mutant allele abundance during tumour progression. This makes mutant CysLT2R an attractive therapeutic target in uveal melanoma.
BACKGROUND: Activating Gαq signalling mutations are considered an early event in the development of uveal melanoma. Whereas most tumours harbour a mutation in GNAQ or GNA11, CYSLTR2 (encoding G-protein coupled receptor CysLT2R) forms a rare alternative. The role of wild-type CysLT2R in uveal melanoma remains unknown. METHODS: We performed a digital PCR-based molecular analysis of benign choroidal nevi and primary uveal melanomas. Publicly available bulk and single cell sequencing data were mined to further study mutant and wild-type CYSLTR2 in primary and metastatic uveal melanoma. RESULTS: 1/16 nevi and 2/120 melanomas carried the CYSLTR2 mutation. The mutation was found in a subpopulation of the nevus, while being clonal in both melanomas. In the melanomas, secondary, subclonal CYSLTR2 alterations shifted the allelic balance towards the mutant. The resulting genetic heterogeneity was confirmed in distinct areas of both tumours. At the RNA level, further silencing of wild-type and preferential expression of mutant CYSLTR2 was identified, which was also observed in two CYSLTR2 mutant primary melanomas and one metastatic lesion from other cohorts. In CYSLTR2 wild-type melanomas, high expression of CYSLTR2 correlated to tumour inflammation, but expression originated from melanoma cells specifically. CONCLUSIONS: Our findings suggest that CYSLTR2 is involved in both early and late development of uveal melanoma. Whereas the CYSLTR2p.L129Q mutation is likely to be the initiating oncogenic event, various mechanisms further increase the mutant allele abundance during tumour progression. This makes mutant CysLT2R an attractive therapeutic target in uveal melanoma.
Entities:
Keywords:
CYSLTR2; Digital PCR; Heterogeneity; Uveal melanoma; Uveal nevus
Authors: Amanda R Moore; Emilie Ceraudo; Jessica J Sher; Youxin Guan; Alexander N Shoushtari; Matthew T Chang; Jenny Q Zhang; Edward G Walczak; Manija A Kazmi; Barry S Taylor; Thomas Huber; Ping Chi; Thomas P Sakmar; Yu Chen Journal: Nat Genet Date: 2016-04-18 Impact factor: 38.330
Authors: Catherine D Van Raamsdonk; Klaus G Griewank; Michelle B Crosby; Maria C Garrido; Swapna Vemula; Thomas Wiesner; Anna C Obenauf; Werner Wackernagel; Gary Green; Nancy Bouvier; M Mert Sozen; Gail Baimukanova; Ritu Roy; Adriana Heguy; Igor Dolgalev; Raya Khanin; Klaus Busam; Michael R Speicher; Joan O'Brien; Boris C Bastian Journal: N Engl J Med Date: 2010-11-17 Impact factor: 91.245
Authors: A Gordon Robertson; Juliann Shih; Christina Yau; Ewan A Gibb; Junna Oba; Karen L Mungall; Julian M Hess; Vladislav Uzunangelov; Vonn Walter; Ludmila Danilova; Tara M Lichtenberg; Melanie Kucherlapati; Patrick K Kimes; Ming Tang; Alexander Penson; Ozgun Babur; Rehan Akbani; Christopher A Bristow; Katherine A Hoadley; Lisa Iype; Matthew T Chang; Andrew D Cherniack; Christopher Benz; Gordon B Mills; Roel G W Verhaak; Klaus G Griewank; Ina Felau; Jean C Zenklusen; Jeffrey E Gershenwald; Lynn Schoenfield; Alexander J Lazar; Mohamed H Abdel-Rahman; Sergio Roman-Roman; Marc-Henri Stern; Colleen M Cebulla; Michelle D Williams; Martine J Jager; Sarah E Coupland; Bita Esmaeli; Cyriac Kandoth; Scott E Woodman Journal: Cancer Cell Date: 2017-08-14 Impact factor: 31.743
Authors: Peter Johansson; Lauren G Aoude; Karin Wadt; William J Glasson; Sunil K Warrier; Alex W Hewitt; Jens Folke Kiilgaard; Steffen Heegaard; Tim Isaacs; Maria Franchina; Christian Ingvar; Tersia Vermeulen; Kevin J Whitehead; Christopher W Schmidt; Jane M Palmer; Judith Symmons; Anne-Marie Gerdes; Göran Jönsson; Nicholas K Hayward Journal: Oncotarget Date: 2016-01-26
Authors: Mark J de Lange; Sake I van Pelt; Mieke Versluis; Ekaterina S Jordanova; Wilma G M Kroes; Claudia Ruivenkamp; Sjoerd H van der Burg; Grégorius P M Luyten; Thorbald van Hall; Martine J Jager; Pieter A van der Velden Journal: Oncotarget Date: 2015-11-10
Authors: M J C Vader; M C Madigan; M Versluis; H M Suleiman; G Gezgin; N A Gruis; J J Out-Luiting; W Bergman; R M Verdijk; M J Jager; P A van der Velden Journal: Br J Cancer Date: 2017-08-15 Impact factor: 7.640
Authors: Catherine D Van Raamsdonk; Vladimir Bezrookove; Gary Green; Jürgen Bauer; Lona Gaugler; Joan M O'Brien; Elizabeth M Simpson; Gregory S Barsh; Boris C Bastian Journal: Nature Date: 2008-12-10 Impact factor: 49.962